1050 related articles for article (PubMed ID: 8837546)
1. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
Jones G; Hogan DB; Yendt E; Hanley DA
CMAJ; 1996 Oct; 155(7):955-61. PubMed ID: 8837546
[TBL] [Abstract][Full Text] [Related]
2. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis.
Murray TM
CMAJ; 1996 Oct; 155(7):935-9. PubMed ID: 8837543
[TBL] [Abstract][Full Text] [Related]
3. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
Murray TM; Ste-Marie LG
CMAJ; 1996 Oct; 155(7):949-54. PubMed ID: 8837545
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.
Siminoski K; Josse RG
CMAJ; 1996 Oct; 155(7):962-5. PubMed ID: 8837547
[TBL] [Abstract][Full Text] [Related]
5. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.
CMAJ; 1996 Oct; 155(8):1113-33. PubMed ID: 8873639
[TBL] [Abstract][Full Text] [Related]
6. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
Hodsman A; Adachi J; Olszynski W
CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
[TBL] [Abstract][Full Text] [Related]
7. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
Josse RG
CMAJ; 1996 Oct; 155(7):929-34. PubMed ID: 8837542
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Role of vitamin D, its metabolites, and analogs in the management of osteoporosis.
Bikle DD
Rheum Dis Clin North Am; 1994 Aug; 20(3):759-75. PubMed ID: 7984788
[TBL] [Abstract][Full Text] [Related]
10. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
[TBL] [Abstract][Full Text] [Related]
13. The vitamin D endocrine system, calcium metabolism, and osteoporosis.
Slovik DM
Spec Top Endocrinol Metab; 1983; 5():83-148. PubMed ID: 6367121
[TBL] [Abstract][Full Text] [Related]
14. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis.
Prior JC; Barr SI; Chow R; Faulkner RA
CMAJ; 1996 Oct; 155(7):940-4. PubMed ID: 8925493
[TBL] [Abstract][Full Text] [Related]
15. [Advantages of active vitamin D metabolites in the treatment of osteoporosis as compared with calciferol].
Zofková I
Vnitr Lek; 2001 Feb; 47(2):99-100. PubMed ID: 15635854
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
De Nijs RN
Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and management of primary osteoporosis.
Bauwens SF; Drinka PJ; Boh LE
Clin Pharm; 1986 Aug; 5(8):639-59. PubMed ID: 3527528
[TBL] [Abstract][Full Text] [Related]
18. Reducing fracture risk with calcium and vitamin D.
Lips P; Bouillon R; van Schoor NM; Vanderschueren D; Verschueren S; Kuchuk N; Milisen K; Boonen S
Clin Endocrinol (Oxf); 2010 Sep; 73(3):277-85. PubMed ID: 20796001
[TBL] [Abstract][Full Text] [Related]
19. Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment.
Lanham-New SA
Proc Nutr Soc; 2008 May; 67(2):163-76. PubMed ID: 18412990
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D receptor ligands for osteoporosis.
Cheskis BJ; Freedman LP; Nagpal S
Curr Opin Investig Drugs; 2006 Oct; 7(10):906-11. PubMed ID: 17086935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
